Avalo Therapeutics (AVTX) Preferred Stock Liabilities (2014 - 2024)
Avalo Therapeutics (AVTX) reported Preferred Stock Liabilities of $1.7 million for Q3 2024, down 85.53% quarter-over-quarter from $11.5 million in Q2 2024.
Avalo Therapeutics (AVTX) Preferred Stock Liabilities (2014 - 2024) Analysis & Trends
Avalo Therapeutics has reported Preferred Stock Liabilities for 3 years, with the latest figure at $1.7 million in Q3 2024.
- For the quarter ending Q3 2024, Preferred Stock Liabilities changed N/A year-over-year to $1.7 million; the trailing twelve-month figure through Sep 2024 stood at $1.7 million (changed N/A YoY), and the FY2014 full-year result was $28.3 million, up 42.75% from the prior year.
- Preferred Stock Liabilities for Q3 2024 stood at $1.7 million, down from $11.5 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $11.5 million in Q1 2024, with the low at $1.7 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Avalo Therapeutics | 295.77 Mn | 295.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 1.66 Mn |
| Jun 30, 2024 | 11.46 Mn |
| Mar 31, 2024 | 11.46 Mn |
| Sep 30, 2015 | 28.35 Mn |
| Dec 31, 2014 | 28.35 Mn |